MedTrace Logo

A Study of Ivonescimab in People With Non-Small Cell Lung Cancer

NCT07594522 · Status: RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 36

Last updated 2026-05-18

No results posted yet for this study

Summary

The researchers are doing this study to find out whether ivonescimab after receiving standard stereotactic body radiotherapy (SBRT) is an effective treatment in people with Non-Small Cell Lung Cancer (NSCLC).

Conditions

Interventions

RADIATION

Photon or Proton standard stereotactic body radiotherapy (SBRT)

Radiation therapy to start within 28 days after enrollment. Radiation therapy will be performed in accordance with institutional standard practice. Proton therapy and photon therapy are allowed as per standard of care in accordance with institutional practice.

DRUG

Ivonescimab

Ivonescimab every 3 weeks on Day 1 of each Cycle as an intravenous (IV).

Sponsors & Collaborators

Principal Investigators

  • Narek Shaverdian, MD · Memorial Sloan Kettering Cancer Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-05-12
Primary Completion
2028-05-12
Completion
2028-05-12
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07594522 on ClinicalTrials.gov